Better Options for Lymphatic Filariasis Treatment
Trial statusNot yet recruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
AgeNot listed
SponsorMedicines Development for Global Health
About this trial
The goal of this clinical trial is to learn if mass drug administration with moxidectin in combination with diethylcarbamazine, and albendazole (MoxDA) can treat lymphatic filariasis, scabies and strongyloidiasis in children and adults living in communities where these diseases are common. The main questions it aims to answer are:
1. Does MoxDA clear infection in people with lymphatic filariasis ? 2. Does MoxDA cause any medical problems in infected and uninfected people?
Researchers will compare MoxDA with ivermectin given together with diethylcarbamazine and albendazole (IDA) to see if it works better to clear infection and does not cause any more medical problems.
Participants will:
1. Be tested to see if they are infected with the parasites that cause lymphatic filariasis, scabies and strongyloidiasis 2. Take 3 single doses of MoxDA or IDA, 12 months apart 3. Visit their village centre once or twice in the 1 week after each treatment for safety checkups
Eligibility criteria
Qualifiers
Provision of signed and dated informed consent.
Resident in one of the study locations.
Disqualifiers
Severe illness (any illness that is severe enough to interfere with activities of daily living);
Known or suspected allergy to ivermectin, moxidectin, diethylcarbamazine or albendazole;
Pregnant;
Breastfeeding a baby within 7 days of birth;
Trial design
Treatments tested in this trial
- MoxDA - Moxidectin + Diethylcarbamzine (DEC) + Albendazole
- IDA - Ivermectin + DEC + albendazole
Treatment groups
5,100 Participants
are divided into 2 treatment groupsSponsors and collaborators
Medicines Development for Global Health
Lead sponsor
Murdoch Childrens Research Institute
Collaborator
Kirby Institute
Collaborator
Source ClinicalTrials.gov